Literature DB >> 15896667

Aurora kinases.

Victor M Bolanos-Garcia1.   

Abstract

Aurora kinases A (also known as Aurora, Aurora-2, AIK, AIR-1, AIRK1, AYK1, BTAK, Eg2, MmIAK1 and STK15), Aurora B (also known as Aurora-1, AIM-1, AIK2, AIR-2, AIRK-2, ARK2, IAL-1 and STK12) and Aurora C (also known as AIK3) participate in several biological processes, including cytokinesis and dysregulated chromosome segregation. These important regulators of mitosis are over-expressed in diverse solid tumors. One member of this family of serine-threonine kinases, human Aurora A, has been proposed as a drugable target in pancreatic cancer. The recent determination of the three-dimensional structure of Aurora A has shown that Aurora kinases exhibit unique conformations around the activation loop region. This property has boosted the search and development of inhibitors of Aurora kinases, which might also function as novel antioncogenic agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15896667     DOI: 10.1016/j.biocel.2005.02.021

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  42 in total

Review 1.  Human T-lymphotropic virus proteins and post-translational modification pathways.

Authors:  Carlo Bidoia
Journal:  World J Virol       Date:  2012-08-12

2.  Probing the structural requirements of A-type Aurora kinase inhibitors using 3D-QSAR and molecular docking analysis.

Authors:  Hui-Xiao Zhang; Yan Li; Xia Wang; Yong-Hua Wang
Journal:  J Mol Model       Date:  2011-04-28       Impact factor: 1.810

3.  Knockdown of Aurora-B inhibits osteosarcoma cell invasion and migration via modulating PI3K/Akt/NF-κB signaling pathway.

Authors:  Liang Bo Zhu; Jian Jiang; Xiao Ping Zhu; Tao Fang Wang; Xuan Yin Chen; Qin Feng Luo; Yong Shu; Zhi Li Liu; Shan Hu Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.

Authors:  Güllü Görgün; Elisabetta Calabrese; Teru Hideshima; Jeffrey Ecsedy; Giulia Perrone; Mala Mani; Hiroshi Ikeda; Giada Bianchi; Yiguo Hu; Diana Cirstea; Loredana Santo; Yu-Tzu Tai; Sabikun Nahar; Mei Zheng; Madhavi Bandi; Ruben D Carrasco; Noopur Raje; Nikhil Munshi; Paul Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2010-04-09       Impact factor: 22.113

5.  Dynamic localization of the human papillomavirus type 11 origin binding protein E2 through mitosis while in association with the spindle apparatus.

Authors:  Luan D Dao; Aaron Duffy; Brian A Van Tine; Shwu-Yuan Wu; Cheng-Ming Chiang; Thomas R Broker; Louise T Chow
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

6.  Mitotic kinase anchoring proteins: the navigators of cell division.

Authors:  Luke J Fulcher; Gopal P Sapkota
Journal:  Cell Cycle       Date:  2020-02-12       Impact factor: 4.534

Review 7.  Mitotic failures in cancer: Aurora B kinase and its potential role in the development of aneuploidy.

Authors:  Katalin Hegyi; Gábor Méhes
Journal:  Pathol Oncol Res       Date:  2012-07-29       Impact factor: 3.201

8.  Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.

Authors:  Jennifer M Sahni; Sylvia S Gayle; Kristen L Weber Bonk; Leslie Cuellar Vite; Jennifer L Yori; Bryan Webb; Erika K Ramos; Darcie D Seachrist; Melissa D Landis; Jenny C Chang; James E Bradner; Ruth A Keri
Journal:  J Biol Chem       Date:  2016-09-20       Impact factor: 5.157

9.  Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.

Authors:  Gerald Falchook; Razelle Kurzrock; Launce Gouw; David Hong; Kimberly A McGregor; Xiaofei Zhou; Hongliang Shi; Howard Fingert; Sunil Sharma
Journal:  Invest New Drugs       Date:  2014-06-01       Impact factor: 3.850

10.  Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma.

Authors:  Xiaoying Shang; Susan M Burlingame; M Fatih Okcu; Ningling Ge; Heidi V Russell; Rachel A Egler; Rodney D David; Sanjeev A Vasudevan; Jianhua Yang; Jed G Nuchtern
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.